You’d think that clinical researchers would welcome surprises - but they don’t. Even if the results are new and groundbreaking, they want their trials and studies to run in a predictable, controlled way,.

And that ability to deliver a total lack of surprise is one of the reasons that cancer research at Nottingham University Hospitals NHS Trust has made it into the top flight in the UK working with major pharmaceutical companies. 

As well as clinical and scientific excellence, it’s about building up relationships with our partners so that we know we can deliver on recruiting patients, managing the pharmacy needs, and study set up. 

The focus is particularly on chemo-free approach to lymphoma treatment, immunotherapy such as CAR T therapy, bispecific antibodies and using data analysis to target treatments.

I talked to Professor Mark Bishton, who’s a consultant haemotologist and the divisional co-lead for research and innovation into cancer and associated. As well as his own research, he’s responsible for delivering the trust’s studies in the specialty.

More information at https://www.nuh.nhs.uk/research-in-cancer

This Podcast is brought to you by the Research & Innovation team at Nottingham University Hospitals NHS Trust. Follow us on @ResearchNUH and @NottmBRC, or email R&Icomms@nuh.nhs.uk.

If you haven't already, please subscribe to the podcast where-ever you get your podcasts, and like/review us on Apple Podcasts especially. It's For Science.